๊ธ๋ฆฌ๋ถ๋ฆฌ๋ (๊ธ๋ฆฌ๋ฒคํด๋ผ๋ฏธ๋)
๊ธ๋ฆฌ๋ถ๋ฆฌ๋(๊ธ๋ฆฌ๋ฒคํด๋ผ๋ฏธ๋๋ผ๊ณ ๋ ํจ)๋ **2์ธ๋ ์คํฌ๋์ฐ๋ ์๊ณ** ๊ฒฝ๊ตฌ์ฉ ํ๋น ๊ฐํ์ ์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก ๊ณ ์์ด์ **์ธ์๋ฆฐ ๋น์์กด์ฑ ๋น๋จ๋ณ(NIDDM)**์ ๋ํ ๋์ฒด ๊ฒฝ๊ตฌ ์น๋ฃ์ ๋ก ์ฌ์ฉ๋ฉ๋๋ค. ์ฃผ์ ์์ ํฌ์ธํธ: * **๊ธ๋ฆฌํผ์ง๋(Glipizide)์ ๋์ฒด์ :** ๊ธ๋ฆฌํผ์ง๋๋ฅผ ๊ตฌํ ์ ์๊ฑฐ๋ ๋ณดํธ์๊ฐ 1์ผ 1ํ ํฌ์ฌ๋ฅผ ๊ฐ๋ ฅํ ์ ํธํ ๋ ์ฃผ๋ก ๊ณ ๋ ค๋ฉ๋๋ค. * **์ธ์๋ฆฐ ์น๋ฃ๊ฐ ์ฐ์ :** ๊ฒฝ๊ตฌ์ฉ ํ๋น ๊ฐํ์ ๋ฅผ ์๋ํด ๋ณผ ์ ์์ง๋ง, **์ธ์๋ฆฐ ์น๋ฃ๊ฐ ์ฌ์ ํ ํ์ค ์น๋ฃ(Gold Standard)**์ด๋ฉฐ ๊ณ ์์ด ๋น๋จ๋ณ์ ์ผ๋ฐ์ ์ผ๋ก ๋ ๊ถ์ฅ๋ฉ๋๋ค. * **ํจ๋ฅ:** ์ฌ๊ฐํ ์ธ์๋ฆฐ ์ ํญ์ฑ์ ๋ณด์ด๊ฑฐ๋ ์ท์ฅ ๋ฒ ํ ์ธํฌ ๊ธฐ๋ฅ์ด ๊ณ ๊ฐ๋ ๊ณ ์์ด์๊ฒ๋ ๊ธ๋ฆฌ๋ถ๋ฆฌ๋๊ฐ ํจ๊ณผ์ ์ด์ง ์์ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Glyburide lowers blood glucose concentrations by stimulating the secretion of endogenous insulin from functional pancreatic beta cells. **Mechanism of Action:** * Binds to **sulfonylurea receptor 1 (SUR1)** subunits on **ATP-sensitive potassium channels (K-ATP)** in the pancreatic beta-cell membrane. * **K-ATP channel closure** โ cell membrane depolarization. * Depolarization triggers the opening of **voltage-dependent calcium channels** โ **Calcium influx**. * Increased intracellular calcium promotes the exocytosis of **insulin** granules. **Extrapancreatic Effects:** With long-term administration, glyburide may also enhance insulin activity at post-receptor sites and reduce basal hepatic glucose production.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Non-insulin dependent diabetes mellitus (NIDDM) ยท 0.625 mg (1/2 of a 1.25 mg tablet) ยท PO ยท once daily ยท Initial dose
- Non-insulin dependent diabetes mellitus (NIDDM) ยท 2.5 mg (total dose) ยท PO ยท twice a day ยท If cat is generally well, weight loss is mild, is not ketoacidotic, and does not have peripheral neuropathy
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Severe burns
- Severe trauma
- Severe infection
- Diabetic coma or other hypoglycemic conditions
- Major surgery
- Ketosis
- Ketoacidosis or other significant acidotic conditions
์ด์๋ฐ์
- Vomiting
- Hypoglycemia
- Liver toxicity (icterus, increased ALT/SGPT)
- Allergic skin reactions (reported in humans)
- Arthralgia (reported in humans)
- Bone marrow suppression (reported in humans)
- Cholestatic jaundice (reported in humans)
์ฝ๋ฌผ ์ํธ์์ฉ
- Alcohol ยท A disulfiram-like reaction (anorexia, nausea, vomiting) is possible
- Azole Antifungals (ketoconazole, itraconazole, fluconazole) ยท May increase plasma levels of glyburide
- Beta-blockers ยท May potentiate hypoglycemic effect
- Chloramphenicol ยท May displace glyburide from plasma proteins
- Cimetidine ยท May potentiate hypoglycemic effect
- Corticosteroids ยท May reduce efficacy
- Thiazide Diuretics ยท May reduce hypoglycemic efficacy
- Isoniazid ยท May reduce hypoglycemic efficacy
- MAO Inhibitors ยท May potentiate hypoglycemic effect
- Niacin ยท May reduce hypoglycemic efficacy
- Phenothiazines ยท May reduce hypoglycemic efficacy
- Phenytoin ยท May reduce hypoglycemic efficacy
- Probenecid ยท May potentiate hypoglycemic effect
- Sulfonamides ยท May displace glyburide from plasma proteins
๋ชจ๋ํฐ๋ง
- Physical examination (weekly during first month)
- Body weight (weekly during first month)
- Urine glucose and ketones (weekly during first month)
- Serial blood glucose exams (weekly during first month)
- Clinical signs of adverse effects (vomiting, icterus)
- Liver enzymes (ALT/SGPT) occasionally
- Complete Blood Count (CBC) occasionally
๊ณผ์ฉ๋
> **Emergency Warning:** Profound **hypoglycemia** is the greatest concern after an overdose. * In humans, severe hypoglycemia has occurred at relatively low dosages. * **Decontamination:** Gut emptying protocols should be employed when warranted and if the patient is neurologically stable. * **Treatment:** Because its half-life is longer than glipizide, prolonged hypoglycemia may occur. Continuous blood glucose monitoring and treatment with parenteral glucose (IV dextrose) may be required for several days. * **Monitoring:** Massive overdoses may also require additional monitoring (blood gases, serum electrolytes) and supportive therapy.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.